Sentences with phrase «lymphoma patients showed»

Data from 29 patients from the single - arm trial in relapsed follicular lymphoma patients showed a 66 % (19 patients) overall response rate — 15 patients were complete responses and 4 patients were partial responses.

Not exact matches

In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatment.

However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells.

A clinical trial has shown that patients with a specific molecular subtype of diffuse large B - cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.

Even lymphoma patients who were «bacteria - free» benefited from a three - week course of doxycycline therapy, and showed complete remission of the disease.

Experience with lymphoma patients, who receive a transplant of their own blood or bone cells after radiation to wipe out their cancer, has shown «there's no doubt it helps,» says bone marrow transplant expert Nelson Chao of Duke University in Durham, North Carolina.

Professor Chris Bunce, Research Director at leukemia & Lymphoma Research, said: «Targeted drugs, like monoclonal antibodies, have shown great promise in recent years in effectively treating a patient's disease while minimising side effects.

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL)-- a rare type of non-Hodgkin lymphoma that affects the skin.

But efforts to develop adoptive T cell therapies for solid tumors have hit upon a number of challenges; the only gene therapies to show significant benefit for patients have been in liquid tumors — forms of leukemia and lymphoma.

One patient treated for extensive chronic GVHD showed a transient response in the liver, but not in the skin and he died of Epstein - Barr virus lymphoma.

However, the data did show that among patients aged 65 to 74, the proportion enrolled in lymphoma and CML trials mirrored the reported incidence of hematologic malignancies in this age group.

«Both total metabolic tumor volume (TMTV), computed on baseline PET, and end - of - induction PET (EOI PET) are imaging biomarkers showing promise for early risk stratification in patients with high tumor - burden follicular lymphoma,» reported lead author Anne Ségolène Cottereau, MD, from Cochin Hospital, René Descartes University, Paris, France, and colleagues.